U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06940401) titled 'JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations' on April 08.
Brief Summary: To evaluate the safety, tolerability, and preliminary efficacy of JS111 capsules in patients with locally advanced, metastatic, or recurrent NSCLC harboring EGFR mutations;to determine the recommended Phase II dose (RP2D).
Study Start Date: April 20
Study Type: INTERVENTIONAL
Condition:
NSCLC
Intervention:
DRUG: JS111 capsules (AP-L1898)
In Phase I, approximately 3-12 subjects will be enrolled in each dose group (160 mg QD or 240 mg QD) and receive oral JS111 capsules once daily until any treatment discontinuation criteria are met. Af...